{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.3","upperLimit":"50.4","value":"5.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"}],"units":"Participants"}],"description":"Time to response was defined as the time (in weeks) from first administration of treatment until first response. Response is defined as complete response (CR) or partial response (PR). CR is defined as the disappearance of all evidence of disease. PR is defined as a regression of measurable disease and no new sites.","dispersionType":"Full Range","groups":[{"description":"Belinostat 1000 mg/m\\^2 administered as a 30 minute IV infusion on Days 1-5 of every 3-week cycle until disease progression or unmanageable treatment-related toxicities.","id":"OG000","title":"Belinostat"}],"paramType":"MEDIAN","populationDescription":"Efficacy Analysis Dataset included participants who received at least 1 dose of belinostat and had a confirmed PTCL diagnosis. Overall number of participants analyzed included responding participants (CR/PR) only.","reportingStatus":"POSTED","timeFrame":"24 months","title":"Time to Response","type":"SECONDARY","unitOfMeasure":"weeks"}